Compare ADMA Biologics Inc (ADMA) vs Amazon.com Inc (AMZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Amazon.com Inc — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Amazon.com Inc trades at $269.35 (market cap $2.94T). The key difference: Amazon.com Inc is far larger — about 1324.3× ADMA Biologics Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AMZN | |
|---|---|---|
Market Cap | $2.22B | $2.94T |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $284.02 |
52-Week Low | $7.60 | $198.79 |
Enterprise Value | $2.29B | $3.04T |
Volume | — | 3,931,282 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Amazon (AMZN) trades at $267.84, down 3.69% over 24 hours, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including a 17.44% net income margin and robust revenue growth to $716.92 billion in 2025. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS and AI chip expansion, fueling investor confidence.
Outlook remains positive with a consensus price target of $333.86, indicating 25% upside potential. Risks include intense competition in e-commerce and cloud services, alongside high capital expenditures. Wall Street sentiment is overwhelmingly bullish, with 89% of analysts rating it a buy, though volatility from macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →
